SIREN : 539438499
ILTOO PHARMA is a French company founded 14 years ago, specialized in the sector Recherche-développement en biotechnologie. Based in PARIS (75013), this company of category PME shows in 2016 a revenue of 1.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-08-01
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
Aucun signal de fragilité majeur : rentabilité positive et structure financière équilibrée.
In summary, ILTOO PHARMA posts positive profitability over the latest financial year. Its financial structure is fragile, with debt above sector norms — a point to monitor.
| Indicator | 2021 | 2016 |
|---|---|---|
| Revenue | N/C | 1 653 138 € |
| Net income | 812 898 € | -615 462 € |
| EBITDA | N/C | -1 097 599 € |
| Net margin | N/C | -37.2% |
In 2021, ILTOO PHARMA generates positive net income of 813 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
1 653 138 €
1 653 138 €
-1 097 599 €
-1 099 425 €
-615 462 €
-50.8%
The debt ratio (= Financial debt / Equity x 100) stands at 117%. This ratio is less favorable than the sector median (9.3%) and warrants attention. Financial autonomy (= Equity / Total assets x 100) reaches 10%. This ratio is less favorable than the sector median (47.8%) and warrants attention.
117.3%
10.34%
-28.41%
-0.81
68.1%
In 2016, the debt ratio of ILTOO PHARMA (117.3%) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2016, the financial autonomy of ILTOO PHARMA (10.3%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
The liquidity ratio (= Current assets / Current liabilities) stands at 3.83. This ratio is slightly less favorable than the sector median (3.1).
3.83
0.0
In 2021, the liquidity ratio of ILTOO PHARMA (2.31) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. WCR is negative (-389 days): operations structurally generate cash.
-1 787 604 €
5 j
74 j
0 j
-389 j
Indicative estimate only : the number of comparable transactions in this sector is limited (36 transactions). This range of 416 398€ to 13 981 122€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 36 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ILTOO PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Recherche-développement en biotechnologie
Largest companies by revenue in the sector Recherche-développement en biotechnologie:
Largest companies by revenue in the department Paris:
The revenue of ILTOO PHARMA in 2016 is 1.7 M€.
Yes, ILTOO PHARMA generated a net profit of 813 k€ in 2021.
The headquarters of ILTOO PHARMA is located in PARIS (75013), in the department Paris.
The tax return of ILTOO PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ILTOO PHARMA operates in the sector Recherche-développement en biotechnologie (NAF code 72.11Z). See the 'Sector positioning' section above to compare the company with its competitors.